Objective The aims of this study were to explore the effect of Profilin-1 on vascular injury caused by advanced glycation end products, So as to provide a new therapeutic approach with diabetic vascular complications.
Methods Human umbilical vein endothelial cells were incubated with different concentrations of AGEs-BSA (50 mg·L−1, 100 mg·L−1, 200 mg·L−1) for various periods of time (6–24 h). The levels of ADMA and NO in the conditioned medium, the protein expression of Profilin-1 for cells were determined.
Results AGEs-BSA increased the protein expression of Profilin-1 and ADMA in a concentration and time-dependent manner. Incubation with high concentration glucose (30 mmol/l) for 24 h elevated the levels of NO, and AGEs-BSA (200 mg·L−1) decrease the levels of NO. AGEs-BSA (200 mg·L−1) could decrease the levels of NO in the conditioned medium, the difference were significant after 24 h.
Conclusion Profilin-1 may be involved in “metabolic memory” induced by the advanced glycation end products.
- Advanced glycation end products
- asymmetric dimethylarginine
- Nitric oxide
- cardiovascular disease
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.